Olema Oncology Announces Positive Phase 2 Monotherapy Clinical Study Results for Palazestrant - Olema Pharmaceuticals (NASDAQ:OLMA)
Across all 86 heavily pretreated patients, the median PFS was 4.6 months with a CBR of 40%; in patients with ESR1 mutations at baseline, the median PFS was 5.6 months with a CBR of 52% In an analysis of 49 second- and